{"id":"al0704rp","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (erythema, swelling, pruritus)"},{"rate":null,"effect":"Systemic allergic reactions"},{"rate":null,"effect":"Oral allergy syndrome (if sublingual formulation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an investigational allergen product from Allergopharma, AL0704rP likely works by gradually inducing immune tolerance to target allergens, potentially through mechanisms involving regulatory T cell expansion and shift from Th2 to Th1/Treg responses. The exact formulation and delivery mechanism are proprietary, but allergen immunotherapies typically aim to reduce allergic symptoms and IgE-mediated responses while increasing blocking IgG antibodies.","oneSentence":"AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:30.074Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design)"}]},"trialDetails":[{"nctId":"NCT00671268","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma","status":"COMPLETED","sponsor":"Allergopharma GmbH & Co. KG","startDate":"2008-03","conditions":"Rhinoconjunctivitis","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["\"na\""],"phase":"phase_3","status":"active","brandName":"AL0704rP","genericName":"AL0704rP","companyName":"Allergopharma GmbH & Co. KG","companyId":"allergopharma-gmbh-co-kg","modality":"Biologic","firstApprovalDate":"","aiSummary":"AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization. Used for Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}